Mixed large cell neuroendocrine carcinoma and mucosa-associated lymphoid tissue lymphoma of the lung: A case report

TAKESHI MATSUMOTO¹, YUKIHIRO IMAI², YASUHIRO KOSAKA³, TAKASHI SHINTANI³ and KEISUKE TOMII¹

Departments of ¹Respiratory Medicine, ²Pathology and ³Radiation Therapy, Kobe City Medical Center General Hospital, Kobe, Hyogo 650-0047, Japan

Received April 19, 2014; Accepted February 10, 2015

Abstract. In the present study, a 79-year-old male was referred to Kobe City Medical Center General Hospital due to an abnormal shadow that was revealed on a chest X-ray. The patient possessed a five-year history of consolidation in the right lower lobe, which was diagnosed as chronic aspiration pneumonia and followed up. However, the abnormal shadow adjacent to the pleura gradually increased in size and a novel mass appeared in the right lower lobe that rapidly increased in size. A repeat biopsy revealed a combination of large cell neuroendocrine carcinoma with a clinical tumor-node-metastasis (cTNM) stage of cT2bN2M0 (stage 3A) and mucosa-associated lymphoid tissue lymphoma at Ann Arbor stage 1E. Chemoradiotherapy markedly affected the lesion and the size of the mass was significantly reduced subsequent to four cycles of chemotherapy, which was considered to be a near complete response. The present study reports an extremely rare combination of tumors. The disease course was followed over a period of six years, which included the onset of disease, and the present case may therefore be valuable in clarifying the mechanism of lung cancer development.

Introduction

Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B cell lymphoma that was first identified by Isaacson and Wright (1). Primary pulmonary lymphoma is rare and accounts for 0.5% of lung tumors, with 72-90% of pulmonary lymphomas being MALT lymphomas (2,3). The outcome of pulmonary MALT lymphoma is generally favorable, with a five-year survival rate of >80% and a median survival time of >10 years (4). At present, no consensus exists with regard to treatment, however, simple clinical monitoring is recommended (5,6). Surgical resection is usually performed in patients with localized lesions, whereas chemotherapy is administered to patients with bilateral or extrapulmonary involvement, relapse or progression (4). Large cell neuroendocrine carcinoma (LCNEC) is a tumor that was first proposed by Travis et al (7). LCNEC is also rare, accounting for 2.4% of lung cancers, and its prognosis is extremely poor with a five-year survival rate of 15-57%, and 27-67% in patients with stage I disease according to TNM staging (8,9). Surgical resection alone is not sufficient for the treatment of LCNEC and thus, adjuvant chemotherapy is recommended after surgery even in patients with stage IA disease according to TNM staging (10). The present study reports a case of a patient with combined LCNEC and MALT lymphoma that responded well to chemoradiotherapy. The combination of these two tumors is extremely rare, and their development was documented over a period of six years, including the onset of disease. The present study may therefore be valuable in clarifying the mechanism of development of lung cancer.

Case report

A 79-year-old male was referred to Kobe City Medical Center General Hospital (Kobe, Japan) with an abnormal shadow that was revealed on a chest X-ray. The patient possessed a history of cerebral infarction, which occurred at 55 years old, had undergone a subtotal gastrectomy for gastric cancer at the age of 70, and had also undergone an aortic arch replacement for thoracic aortic aneurysm at 75 years old. The patient was an ex-smoker, and had not experienced apparent asbestos or silica dust exposure. Follow-up had been performed at Rokko Island Hospital (Kobe, Japan) for the five years prior to the referral (Fig. 1A). Medical attention had been sought at Rokko Island Hospital three years prior to referral for hemoptysis, and a consolidation in the right lower lung field was identified at that time (Fig. 1B). The consolidation was followed up as chronic aspiration pneumonia. Bronchoscopy was performed two years prior to the current admission as the consolidation adjacent to the pleura had enlarged (Fig. 1C), but no specific findings were noted. The consolidation was considered to be chronic aspiration pneumonia since the size varied over time, but it had gradually increased in size in the five years prior to the referral. The patient was referred to Kobe City Medical
Center General Hospital as a novel mass in the right lower lobe had appeared and rapidly increased in size, which was accompanied by elevation of soluble interleukin-2 receptor (sIL2R; Fig. 1D and E).

Physical examination revealed that respiratory sounds were decreased in the right lower lung. A chest radiograph revealed a mass and consolidation in the right lower lung. A computed tomography scan revealed an expanding mass and consolidation in a region of emphysema adjacent to the pleura in the right lower lobe (Fig. 1E). A positron emission tomography scan revealed high uptake of fluorodeoxyglucose in the mass in the right lower lobe and the mediastinal lymph nodes (SUV$_{\text{max}}$, 24.3) but the uptake was low in the consolidation region (SUV$_{\text{max}}$, 3.5) (Fig. 2). Laboratory examinations revealed a white blood cell count of 12400 cells/mm$^3$, comprising 82% neutrophils, a C-reactive protein level of 6.4 mg/dl, a neuron-specific enolase level of 19.2 ng/ml, a progastrin-releasing peptide level of 33.8 pg/ml, a carcinoembryonic antigen level of 5.4 ng/ml, a cytokeratin 19 fragment...
level of 3.4 ng/ml, a squamous cell carcinoma-related antigen level of 2.1 ng/ml, and a sIL2R level of 1756 units/ml. Histological examination of repeat bronchoscopic and echo-guided biopsies of the right mass and consolidation revealed two types of abnormal cells (Fig. 3A). One cell type was carcinoma exhibiting a rosette pattern (Fig. 3B), which was positive for cytokeratin and cluster of differentiation (CD)56 expression, while the other cell type was aggregated small lymphocytes (Fig. 3C) that were CD20-negative but CD3-negative. Certain regions were positive for CD56 expression, while other areas in the tumor were positive for CD20 expression (Fig. 3D and E), which was considered a mix of neuroendocrine carcinoma, either LCNEC or small cell carcinoma, and MALT lymphoma. Endobronchial ultrasound-guided transbronchial needle aspiration was performed on the swollen 4R lymph node to determine the stage of the lesion. The aspiration revealed a medium to large-sized endocrine carcinoma, with a rosette pattern that was diffusely cytokeratin-positive and did not express CD20 and CD56. Therefore, it was hypothesized that the lesion resulted from the metastasis of LCNEC. The patient was diagnosed with LCNEC at a clinical tumor-node-metastasis stage (cTNM) of cT2bN2M0 (stage 3A) and MALT lymphoma at Ann Arbor stage 1E.

Chemotherapy, consisting of carboplatin (area under the curve, 4; day 1) and etoposide (80 mg/m²; days 1-3),
combined with radiation therapy (45 Gy; 30 fractions) were commenced, which markedly affected the mass and consolidation (Fig. 4). Subsequent to four cycles of chemotherapy, the mass was significantly reduced in size and the consolidation was also reduced (Fig. 5). The effect was considered to be a near-complete response, which continued for 144 days. Subsequently, liver and bone metastases appeared and the patient declined further chemotherapy. Although the lung tumor and consolidation did not enlarge, the metastatic lesions increased in size. Eight months subsequent to referral, the patient succumbed to hepatic failure caused by liver metastasis.

Discussion

The present study, to the best of our knowledge, reports the first case of a patient with combined LCNEC and MALT lymphoma of the lung that responded well to chemoradiotherapy and was followed over six years.

MALT lymphoma is a low grade B cell lymphoma that mostly occurs in the gastrointestinal tract, accounting for only 0.5% of lung tumors. Therefore, pulmonary MALT lymphoma is extremely rare (2,3). LCNEC is a tumor that is regarded as a variant of large cell carcinoma by the World Health Organization. LCNEC is also rare, accounting for 2.4% of lung cancers. The biological features of LCNEC are similar to those of small cell carcinoma and the prognosis is extremely poor (8,9). Surgery is performed to treat LCNEC, if possible, but the current results are not satisfactory. Although a standard therapy for LCNEC has not been established, chemoradiotherapy similar to that administered for the treatment of small cell carcinoma is administered to patients with inoperable LCNEC (11).

It has been speculated that MALT lymphoma of the lung is associated with chronic respiratory infection, chronic inflammatory diseases, autoimmune diseases or antigen exposure, such as exposure to tobacco (12,13). The median time to progression for pulmonary MALT lymphoma has been reported to be 5.6 years, and the prognosis was the same regardless of whether treatment consisted of chemotherapy or surgery (14,15). In addition, Troch et al (6) reported that pulmonary MALT lymphoma may not require immediate treatment in asymptomatic patients and thus, a watch-and-wait strategy may be adopted.

Cases of combined MALT lymphoma and gastric cancer have been reported frequently. However, the combination of lung cancer with MALT lymphoma is rare and few cases have been reported at present (16-21). To the best of our knowledge, the combination of LCNEC and MALT lymphoma has been reported in only one other case (18), in which the patient suffered from sarcoidosis. Surgery was performed for the treatment of a mass shadow in the left lower lobe of the lung, and the concurrent occurrence of LCNEC and MALT lymphoma was an incidental finding. In the present case, the consolidation adjacent to the pleura was thought to be MALT lymphoma and the novel mass was LCNEC, since the consolidation appeared initially and increased in size extremely slowly, whereas the mass appeared later and rapidly became enlarged.

As the combination of lung cancer with MALT lymphoma is rare, the mechanism is not well-elucidated. However, possible causes of the formation of MALT lymphoma and lung cancer were reported to be either associated with the API2-MALT1 fusion gene or smoking (16,17). By contrast, when the rate of combination of malignant lymphoma with other types of cancer was statistically analyzed, the combination with lung cancer was reported to be a coincidental occurrence (22). The present patient was followed for six years, and this observation may indicate that stimulation from the MALT lymphoma contributed to the formation of lung cancer. However, there is insufficient data on the combination of lung cancer with MALT lymphoma. This concept requires further elucidation through the examination of additional cases.

In conclusion, the present study reported the case of a patient with combined LCNEC and MALT lymphoma of the lung that was followed over six years, including the onset of the disease.
References


